Switch theme
Sign up to access all valuation multiples
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
2006
790
LTM Revenue $719M
LTM EBITDA $219M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pacira BioSciences has a last 12-month revenue (LTM) of $719M and a last 12-month EBITDA of $219M.
In the most recent fiscal year, Pacira BioSciences achieved revenue of $701M and an EBITDA of $29.1M.
Pacira BioSciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pacira BioSciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $719M | XXX | $701M | XXX | XXX | XXX |
| Gross Profit | $555M | XXX | $531M | XXX | XXX | XXX |
| Gross Margin | 77% | XXX | 76% | XXX | XXX | XXX |
| EBITDA | $219M | XXX | $29.1M | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 4% | XXX | XXX | XXX |
| EBIT | $193M | XXX | $97.6M | XXX | XXX | XXX |
| EBIT Margin | 27% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $150M | XXX | -$99.6M | XXX | XXX | XXX |
| Net Margin | 21% | XXX | -14% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $309M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Pacira BioSciences's stock price is $26.
Pacira BioSciences has current market cap of $1.2B, and EV of $1.3B.
See Pacira BioSciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.2B | XXX | XXX | XXX | XXX | $3.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Pacira BioSciences has market cap of $1.2B and EV of $1.3B.
Pacira BioSciences's trades at 1.9x EV/Revenue multiple, and 46.0x EV/EBITDA.
Equity research analysts estimate Pacira BioSciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pacira BioSciences has a P/E ratio of 8.0x.
See valuation multiples for Pacira BioSciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | 6.1x | XXX | 46.0x | XXX | XXX | XXX |
| EV/EBIT | 6.9x | XXX | 13.7x | XXX | XXX | XXX |
| EV/Gross Profit | 2.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 8.0x | XXX | -12.0x | XXX | XXX | XXX |
| EV/FCF | 7.8x | XXX | 7.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPacira BioSciences's last 12 month revenue growth is 9%
Pacira BioSciences's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.5M for the same period.
Pacira BioSciences's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pacira BioSciences's rule of X is 52% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pacira BioSciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 17% | XXX | XXX | XXX |
| Rule of 40 | 32% | XXX | 13% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 52% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 62% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pacira BioSciences acquired XXX companies to date.
Last acquisition by Pacira BioSciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Pacira BioSciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Pacira BioSciences founded? | Pacira BioSciences was founded in 2006. |
| Where is Pacira BioSciences headquartered? | Pacira BioSciences is headquartered in United States of America. |
| How many employees does Pacira BioSciences have? | As of today, Pacira BioSciences has 790 employees. |
| Who is the CEO of Pacira BioSciences? | Pacira BioSciences's CEO is Mr. Frank D. Lee. |
| Is Pacira BioSciences publicy listed? | Yes, Pacira BioSciences is a public company listed on NAS. |
| What is the stock symbol of Pacira BioSciences? | Pacira BioSciences trades under PCRX ticker. |
| When did Pacira BioSciences go public? | Pacira BioSciences went public in 2011. |
| Who are competitors of Pacira BioSciences? | Similar companies to Pacira BioSciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Pacira BioSciences? | Pacira BioSciences's current market cap is $1.2B |
| What is the current revenue of Pacira BioSciences? | Pacira BioSciences's last 12 months revenue is $719M. |
| What is the current revenue growth of Pacira BioSciences? | Pacira BioSciences revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Pacira BioSciences? | Current revenue multiple of Pacira BioSciences is 1.9x. |
| Is Pacira BioSciences profitable? | Yes, Pacira BioSciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Pacira BioSciences? | Pacira BioSciences's last 12 months EBITDA is $219M. |
| What is Pacira BioSciences's EBITDA margin? | Pacira BioSciences's last 12 months EBITDA margin is 30%. |
| What is the current EV/EBITDA multiple of Pacira BioSciences? | Current EBITDA multiple of Pacira BioSciences is 6.1x. |
| What is the current FCF of Pacira BioSciences? | Pacira BioSciences's last 12 months FCF is $171M. |
| What is Pacira BioSciences's FCF margin? | Pacira BioSciences's last 12 months FCF margin is 24%. |
| What is the current EV/FCF multiple of Pacira BioSciences? | Current FCF multiple of Pacira BioSciences is 7.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
